Breaking News
Sort by:
Top Post
Experimental Cancer Drug May Slow Inflammation Linked to Heart Disease
An experimental drug already tested as a potential treatment for cancer, lung, and Alzheimer’s disease […]
Amarna Therapeutics Announces Appointment of Dr. Henk Streefkerk as New CEO
Amarna Therapeutics, a privately-held biotechnology company developing transformative gene therapies in a range of rare […]
ENSEM Announces the Promotion of Shengfang Jin, PhD to President & Chief Executive Officer
Ensem Therapeutics, a biotechnology company focusing on high-value and difficult-to-drug oncology targets, today announced the […]
Visgenx Appoints William Pedranti as Chief Executive Officer
Visgenx, a biotechnology company focused on developing gene therapies for degenerative retinal diseases, today announced […]
HuidaGene Therapeutics Appoints Alvin Luk as Chief Executive Officer
HuidaGene Therapeutics, a clinical-stage genome-editing company, today announced the appointment of gene therapy industry veteran, […]
Obsidian Therapeutics Announces Dr. Madan Jagasia as Chief Executive Officer and Other Leadership Appointments
Obsidian Therapeutics, a clinical-stage biotechnology company pioneering engineered cell and gene therapies, today announced the […]
Niklas Prager Appointed New CEO of SmartCella
SmartCella Holding AB has today announced that Niklas Prager has been appointed as the new […]
Vicinitas Therapeutics Appoints Christian Hofmann, Ph.D., as Chief Executive Officer
Vicinitas Therapeutics, a biotechnology company advancing a proprietary targeted protein stabilization platform to develop novel […]
Engimmune Therapeutics Appoints Dr. Lars Nieba as Chief Executive Officer
Engimmune Therapeutics, a Swiss biotech company developing novel T-cell receptor (TCR)-based therapeutics, today announces the […]
Standigm Announces Younsung Choo as Chief Executive Officer (CEO)
Standigm, a company using artificial intelligence (AI) technology for drug discovery and development, announced that Younsung […]
Abivax Appoints Marc de Garidel as Chief Executive Officer and Interim Board Chair
Abivax, a Phase 3 clinical-stage biotechnology company focused on developing therapeutics that modulate the immune […]
- Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Read more
- Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS Read more
- DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Read more
- Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Read more
- Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Read more